Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Notches “Milestone” In OTC Switch Plan

This article was originally published in The Tan Sheet

Executive Summary

Nexium 24HR’s is “the first significant milestone” Pfizer’s Rx-to-OTC strategy, says Albert Bourla, head of the division that includes consumer products. The next milestone could be a new drug application for an OTC version of Lipitor.

You may also be interested in...



Perrigo Counts 32 Billion Reasons To Reject Mylan Offers

In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.

Perrigo Counts 32 Billion Reasons To Reject Mylan Offers

In addition to announcing it to turned down Mylan’s offer of $205 per share or roughly $28.9 billion, Perrigo reports a 41% increase in adjusted net income to a company-record $248.5 million in its latest quarter. The firm plans to launch a generic of Sanofi’s Nasacort 24 HR in time for the 2015 allergy season.

Pfizer Lipitor OTC Bid Would Face FDA Evolving On Switch Innovation

Pfizer looks to lessons from prior statin attempts and an environment open to new ways to inform consumer decisions as it considers filing for a Lipitor switch, which will depend on the outcome of a large actual use trial.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel